- In December 2023, Max Healthcare successfully introduced CAR-T cell therapy in the Delhi-NCR area, marking a significant advancement in cancer treatment options. This innovative therapy, developed in partnership with ImmunoACT, is specifically designed to combat lymphomas and leukemias, offering new hope for patients battling these challenging conditions
- In December 2022, CARsgen Therapeutics Co., Ltd. partnered with the Shanghai Cancer Institute to develop new technology that significantly enhances the antitumor effectiveness of T cells. Their research team discovered that CAR T cells engineered to overexpress Runx3 exhibited sustained antitumor activity and improved tumor control compared to traditional chimeric antigen receptor T-cell therapies
- In November 2022, Caribou Biosciences, Inc. announced that its allogeneic anti-CD19 CAR-T cell therapy, CB-010, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory large B cell lymphoma (LBCL), as well as fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma
- In June 2022, The University of Ottawa showcased promising results from the Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) clinical trial, which focused on one of the first Canadian-developed CAR-T cell therapies for cancer. This therapy features a unique manufacturing process that may lead to more affordable and equitable treatment options
- In November 2021, The California Institute for Regenerative Medicine's governing board approved a grant of USD 4.1 million to support the advancement of innovative chimeric antigen receptor T-cell therapy being developed by scientists at the University of California San Diego School of Medicine, aiding their efforts to transition this promising cancer treatment from the laboratory to clinical practice
Frequently Asked Questions
The market is segmented based on Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Segmentation, By Types (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Target Antigen (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, Egfrvlll, and Others), Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasts, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular, Carcinoma, Colorectal Cancer, and Others) – Industry Trends and Forecast to 2031
.
The Global Car T Cell Therapy Market size was valued at USD 2.44 USD Billion in 2023.
The Global Car T Cell Therapy Market is projected to grow at a CAGR of 11.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
